Financial update for Q2 2025 reveals Butterfly Network's latest financial standing
KLA Corporation Reports Strong Financial Performance for Fiscal Year 2025
In a significant development, KLA Corporation has announced its financial results for the fiscal year 2025, showcasing a robust performance that has earned it accolades from various prestigious organisations.
The tech giant reported total revenues of $12.16 billion for the year, with GAAP net income of $4.06 billion and GAAP diluted EPS of $30.37. The fourth quarter saw revenues of $3.175 billion, close to the upper end of guidance, and a GAAP diluted EPS of $9.06, also at the upper end of guidance. These figures indicate a strong performance relative to expectations for the year.
KLA demonstrated its financial strength by improving its Adjusted EBITDA guidance. The company showed robust cash flow from operations and free cash flow, with quarterly free cash flow exceeding $1 billion for the first time in the June quarter. Full year cash flow from operations was $4.08 billion, and free cash flow was $3.75 billion. Capital returns totalled $3.05 billion for the fiscal year, indicating strong financial health and shareholder returns.
Other companies in the same sector, such as Azenta and FiscalNote, have also provided their fiscal 2025 revenue guidance. However, KLA's report stands out as the most detailed, providing a comprehensive overview of full year revenue and improved Adjusted EBITDA guidance.
Butterfly Network's Innovations Recognised
Elsewhere, Butterfly Network, a healthcare company driving a digital revolution in medical imaging, has been recognised by Fierce 50, TIME's Best Inventions, and Fast Company's World Changing Ideas, among others.
Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. The company launched the world's first handheld, single-probe, whole-body ultrasound system, Butterfly iQ, in 2018, followed by the iQ+ in 2020 and the iQ3 in 2024. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards.
Clinical publications demonstrate that Butterfly's handheld ultrasound probes paired with CompassTM enterprise workflow software can help hospital systems improve care workflows, reduce costs, and enhance provider economics.
Conference Call and Financial Statements
KLA will hold a conference call and webcast to discuss its second quarter 2025 financial performance and operational progress on August 1, 2025, at 8:00 am ET. The call will be broadcast live in listen-only mode via KLA's Investor Relations website at Events & Presentations. After the live webcast, the call will be archived on KLA's Investor Relations page.
For those who wish to attend, the access code is 685760. US domestic callers can dial +1 833-470-1428, international callers can dial 1 404-975-4839, and global dial-in numbers are available at https://www.netroadshow.com/conferencing/global-numbers?confId=82507.
A telephone replay of the call will be available until August 15, 2025, by dialing 1 929 458 6194 (United States local) or 1 866 813 9403 (United States toll-free), with Access Code 128350.
Butterfly encourages investors to review financial statements and publicly filed reports in their entirety and not to rely on any single financial measure. In addition to providing financial measures based on generally accepted accounting principles in the United States of America ("GAAP"), Butterfly provides non-GAAP financial measures such as adjusted gross profit, adjusted gross margin, adjusted EBITDA, and adjusted EPS.
Butterfly aims to democratize healthcare by addressing critical global healthcare challenges with a cloud-based solution that enables care anywhere through next-generation mobility. The company's devices are commercially available to trained healthcare practitioners in various regions, including Africa, Asia, Australia, Europe, the Middle East, North America, and South America.
Caution Regarding Forward-Looking Statements
The press release includes forward-looking statements that may differ from expectations due to known and unknown risks and uncertainties. The forward-looking statements involve significant known and unknown risks and uncertainties and other factors that could cause actual results to differ materially from those discussed in the forward-looking statements.
Butterfly's non-GAAP financial measures may not be comparable to similarly titled measures of other companies because they may not calculate these measures in the same manner. The forward-looking statements include expectations with respect to financial results, commercialization and plans to deploy products and services, and the size and potential growth of current or future markets for products and services.
Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. KLA and Butterfly undertake no obligation to update or revise the forward-looking statements, except as may be required by law.
The KLA Corporation's financial report for fiscal year 2025 highlighted a strong performance, particularly in cloud technology, as the tech giant surpassed its revenue and profitability guidance. Meanwhile, Butterfly Network, a pioneer in medical imaging, has been recognized for its technological innovations and is working towards democratizing healthcare with a cloud-based solution for global accessibility.
